Skip to search formSkip to main contentSkip to account menu

HPA 23

Known as: HPA-23, Heteropolyanion-23 
National Institutes of Health

Related topics

Related topics

1 relation
5-tungsto-2-antimoniate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection
SummaryThe effects of up to 12 daily doses of HPA-23 (ammonium 5-tungsto-2-antimoniate) on scrapie were studied using five… 
1994
1994
Use of a flavivirus RNA-dependent RNA polymerase assay to investigate the antiviral activity of selected compounds.
Highly Cited
1990
Highly Cited
1990
Anti-HIV-1 activity, toxicity, and stability studies of representative structural families of polyoxometalates.
The anti-HIV-1 activity and toxicity of representative structural families of polyoxotungstates in human lymphocytes was… 
1989
1989
Lack of HPA-23 antiviral activity in HIV-infected patients without AIDS.
A randomized study of 12 treated patients and seven controls was conducted in order to evaluate HPA-23 anti-HIV activity in HIV… 
Highly Cited
1988
Highly Cited
1988
Clinical trial of tolerance of HPA-23 in patients with acquired immune deficiency syndrome
An open-label, multicenter clinical trial assessed the tolerance of HPA-23 (ammonium-21-tungsto-9-antimoniate) in patients with… 
Review
1988
Review
1988
Antiviral drugs other than zidovudine and immunomodulating therapies in human immunodeficiency virus infection. An overview.
Although the management of patients with human immunodeficiency virus infections has focused on the treatment of opportunistic… 
Highly Cited
1986
Highly Cited
1986
Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions
Studies of polyanions that suppress scrapie have been done to pinpoint the cell types in the lymphoreticular system which are… 
Highly Cited
1986
Highly Cited
1986
Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV)
Suramin and various other selected compounds were evaluated for their in vitro inhibitory effects on the infectivity and… 
Review
1985
Review
1985
Prospects of therapy for infections with human T-lymphotropic virus type III.
Human T-lymphotropic virus type III is susceptible to attack at various sites during its replicative cycle. Inhibitors of reverse… 
1984
1984
Modulation by the polyoxotungstate HPA-23 of Epstein-Barr virus early antigen expression in Raji cells treated with iododeoxyuridine.
The polyoxotungstate HPA-23 was found to exert a differential effect on the induction of Epstein-Barr virus early antigen in Raji… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)